BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1009 related articles for article (PubMed ID: 15534046)

  • 21. Evaluation of therapy for lymphoma.
    Jerusalem G; Hustinx R; Beguin Y; Fillet G
    Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
    García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
    Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
    Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Noninvasive assessment of pediatric inflammatory bowel disease with ¹⁸F-fluorodeoxyglucose-positron emission tomography and computed tomography.
    Däbritz J; Jasper N; Loeffler M; Weckesser M; Foell D
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):81-9. PubMed ID: 21042220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
    Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
    Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary Tumor ¹⁸F-FDG Avidity Affects the Performance of ¹⁸F-FDG PET/CT for Detecting Gastric Cancer Recurrence.
    Kim SJ; Cho YS; Moon SH; Bae JM; Kim S; Choe YS; Kim BT; Lee KH
    J Nucl Med; 2016 Apr; 57(4):544-50. PubMed ID: 26678615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
    Basu S; Mahne A; Iruvuri S; Alavi A
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
    Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
    J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of disease progression after palliative chemotherapy in NSCLC patients by (18)F-FDG-PET.
    Tauhardt E; Reissig A; Winkens T; Freesmeyer M
    Nuklearmedizin; 2014; 53(5):197-204. PubMed ID: 24986272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
    Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
    Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
    Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
    Liu Y
    Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis.
    Zhu HJ; Halkar R; Alavi A; Goris ML
    Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency].
    Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.